Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways

ABSTRACT Toll-like receptors (TLRs) are key components of the innate immune system that trigger antimicrobial host defense responses. The aim of the present study was to analyze the effects of probiotic Escherichia coli Nissle strain 1917 in experimental colitis induced in TLR-2 and TLR-4 knockout mice. Colitis was induced in wild-type (wt), TLR-2 knockout, and TLR-4 knockout mice via administration of 5% dextran sodium sulfate (DSS). Mice were treated with either 0.9% NaCl or 107E. coli Nissle 1917 twice daily, followed by the determination of disease activity, mucosal damage, and cytokine secretion. wt and TLR-2 knockout mice exposed to DSS developed acute colitis, whereas TLR-4 knockout mice developed significantly less inflammation. In wt mice, but not TLR-2 or TLR-4 knockout mice, E. coli Nissle 1917 ameliorated colitis and decreased proinflammatory cytokine secretion. In TLR-2 knockout mice a selective reduction of gamma interferon secretion was observed after E. coli Nissle 1917 treatment. In TLR-4 knockout mice, cytokine secretion was almost undetectable and not modulated by E. coli Nissle 1917, indicating that TLR-4 knockout mice do not develop colitis similar to the wt mice. Coculture of E. coli Nissle 1917 and human T cells increased TLR-2 and TLR-4 protein expression in T cells and increased NF-κB activity via TLR-2 and TLR-4. In conclusion, our data provide evidence that E. coli Nissle 1917 ameliorates experimental induced colitis in mice via TLR-2- and TLR-4-dependent pathways.

[1]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[2]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[3]  G. Macfarlane,et al.  Toll‐like receptors‐2, ‐3 and ‐4 expression patterns on human colon and their regulation by mucosal‐associated bacteria , 2005, Immunology.

[4]  G. T. te Meerman,et al.  Association Between Toll‐like Receptor 4 and Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[5]  H. Qin,et al.  Effect of lactobacillus on the gut microflora and barrier function of the rats with abdominal infection. , 2005, World journal of gastroenterology.

[6]  A. Zeng,et al.  Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. , 2005, Journal of biotechnology.

[7]  H. Volk,et al.  Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin‐1&bgr;, Interleukin‐8, and Interferon‐&ggr; Gene Expression , 2005 .

[8]  T. Hibi,et al.  Nonpathogenic Escherichia coli Strain Nissle1917 Prevents Murine Acute and Chronic Colitis , 2005, Inflammatory bowel diseases.

[9]  E. Cario BACTERIAL INTERACTIONS WITH CELLS OF THE INTESTINAL MUCOSA: TOLL-LIKE RECEPTORS AND NOD2 , 2005, Gut.

[10]  B. Wiedenmann,et al.  Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling , 2005, Infection and Immunity.

[11]  M. Guslandi Antibiotics for inflammatory bowel disease: do they work? , 2005, European journal of gastroenterology & hepatology.

[12]  A. Dignass,et al.  Current biological therapies for inflammatory bowel disease. , 2004, Current pharmaceutical design.

[13]  K. Michaelsen,et al.  Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. , 2004, The Journal of pediatrics.

[14]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[15]  J. Jacobberger,et al.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitis , 2004, Gut.

[16]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[17]  W. Kruis,et al.  Antibiotics and probiotics in inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[18]  G. Gottschalk,et al.  Analysis of the Genome Structure of the Nonpathogenic Probiotic Escherichia coli Strain Nissle 1917 , 2004, Journal of bacteriology.

[19]  C. Mcnaught,et al.  Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomised controlled trial. , 2004, Clinical nutrition.

[20]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[21]  M. Sans,et al.  Inflammatory bowel disease: the role of environmental factors. , 2004, Autoimmunity reviews.

[22]  L. Mayer,et al.  Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. , 2004, Gastroenterology.

[23]  G. Greenberg Antibiotics should be used as first-line therapy for Crohn's disease. , 2004, Inflammatory bowel diseases.

[24]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[25]  S. Akira,et al.  Toll-Like Receptors Are Temporally Involved in Host Defense , 2004, The Journal of Immunology.

[26]  J. Schölmerich,et al.  Preventive Effects of Escherichia coli Strain Nissle 1917 on Acute and Chronic Intestinal Inflammation in Two Different Murine Models of Colitis , 2004, Clinical Diagnostic Laboratory Immunology.

[27]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[28]  C. Neut,et al.  Self inflicted rectal ulcer: hearing is believing , 2003, Gut.

[29]  J. Schölmerich,et al.  Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases , 2003, Digestive Diseases.

[30]  Gregor Reid,et al.  Potential Uses of Probiotics in Clinical Practice , 2003, Clinical Microbiology Reviews.

[31]  U. Göbel,et al.  Lipoteichoic Acid (LTA) of Streptococcus pneumoniaeand Staphylococcus aureus Activates Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved* , 2003, The Journal of Biological Chemistry.

[32]  B. Wiedenmann,et al.  Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.

[33]  J. Udagawa,et al.  Strategic Compartmentalization of Toll-Like Receptor 4 in the Mouse Gut1 , 2003, The Journal of Immunology.

[34]  C. Loddenkemper,et al.  Role of Gamma Delta T Cells in Inflammatory Bowel Disease , 2003, Pathobiology.

[35]  D. Polk,et al.  Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial Cells* , 2002, The Journal of Biological Chemistry.

[36]  G. Gottschalk,et al.  A Single Nucleotide Exchange in the wzy Gene Is Responsible for the Semirough O6 Lipopolysaccharide Phenotype and Serum Sensitivity of Escherichia coli Strain Nissle 1917 , 2002, Journal of bacteriology.

[37]  P. Gionchetti,et al.  Treatment of mild to moderate ulcerative colitis and pouchitis , 2002, Alimentary pharmacology & therapeutics.

[38]  Jongdae Lee,et al.  Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. , 2002, Gastroenterology.

[39]  Adrian Ozinsky,et al.  Toll-like receptors: key mediators of microbe detection. , 2002, Current opinion in immunology.

[40]  S. Akira,et al.  Toll-like receptors control activation of adaptive immune responses , 2001, Nature Immunology.

[41]  G. Reid,et al.  Can bacterial interference prevent infection? , 2001, Trends in microbiology.

[42]  U. Göbel,et al.  Toll-like Receptor-2 Mediates Treponema Glycolipid and Lipoteichoic Acid-induced NF-κB Translocation* , 2001, The Journal of Biological Chemistry.

[43]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[44]  S. Akira,et al.  Expression of Toll-Like Receptor 2 on γδ T Cells Bearing Invariant Vγ6/Vδ1 Induced by Escherichia coli Infection in Mice1 , 2000, The Journal of Immunology.

[45]  R. Blumberg,et al.  Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. , 1999, Current opinion in immunology.

[46]  S. Akira,et al.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. , 1999, Immunity.

[47]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[48]  Yoshinori Nagai,et al.  MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4 , 1999, The Journal of experimental medicine.

[49]  R. N. Smith,et al.  Colitis in transgenic and knockout animals as models of human inflammatory bowel disease , 1999, Immunological reviews.

[50]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[51]  G. Jung,et al.  Structure and Specific Activity of Macrophage-Stimulating Lipopeptides from Mycoplasma hyorhinis , 1998, Infection and Immunity.

[52]  C. Fiocchi Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[53]  H A Malchow,et al.  Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? , 1997, Journal of clinical gastroenterology.

[54]  M. Stolte,et al.  Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis , 1997, Alimentary pharmacology & therapeutics.

[55]  K. Ewe,et al.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) , 1995, Clinical and experimental immunology.

[56]  D. Rachmilewitz,et al.  Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. , 1995, Gut.

[57]  J. Hacker,et al.  Properties ofEscherichia coli strains of serotype O6 , 1995, Infection.

[58]  M. Leach,et al.  Genetic and spontaneous models of inflammatory bowel disease in rodents: evidence for abnormalities in mucosal immune regulation. , 1995, Therapeutic immunology.

[59]  T. Klaenhammer,et al.  Genetics of bacteriocins produced by lactic acid bacteria. , 1993, FEMS microbiology reviews.

[60]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[61]  L. Vuyst,et al.  Bacteriocins of Lactic Acid Bacteria , 1994 .

[62]  W. Strober Animal models of inflammatory bowel disease—An overview , 1985, Digestive Diseases and Sciences.

[63]  F. Shanahan,et al.  Probiotics: an emerging therapy. , 2005, Current pharmaceutical design.

[64]  R. Medzhitov,et al.  Toll-like receptors: linking innate and adaptive immunity. , 2004, Microbes and infection.

[65]  H. Volk,et al.  Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. , 2005, Inflammatory bowel diseases.

[66]  W. Kruis Review article: antibiotics and probiotics in inflammatory bowel disease. , 2004, Alimentary pharmacology & therapeutics.

[67]  Shizuo Akira,et al.  MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis , 2004, Journal of Gastroenterology.

[68]  A. Sturm,et al.  Probiotika bei chronisch entzündlichen Darmerkrankungen , 2003 .

[69]  J. Hacker,et al.  Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. , 2003, Research in microbiology.

[70]  R. Schumann,et al.  TLR2: cellular sensor for microbial and endogenous molecular patterns. , 2002, Current topics in microbiology and immunology.

[71]  Manfred Dietel,et al.  Mucosal flora in inflammatory bowel disease. , 2002, Gastroenterology.

[72]  B. Beutler,et al.  TLR4 as the mammalian endotoxin sensor. , 2002, Current topics in microbiology and immunology.

[73]  P. Godowski,et al.  Toll-Like Receptor 2 Ligands as Adjuvants for Human Th1 Responses , 2002 .

[74]  S. Akira,et al.  Expression of toll-like receptor 2 on gamma delta T cells bearing invariant V gamma 6/V delta 1 induced by Escherichia coli infection in mice. , 2000, Journal of immunology.